Sabrina Serani

The combination of and investigational immune checkpoint inhibitor, immunotherapy, and antibody-drug conjugate showed improvements in overall survival in patients with a variety of human papillomavirus-positive cancers.

THIO has received 2 prior orphan drug designations, and the agent has shown promise in preclinical studies for the treatment of glioblastoma.

In patients with metastatic castration-resistant prostate cancer of the adenocarcinoma phenotype, the combination of BXCL701 and pembrolizumab led to a median overall survival of 15.5 months.

The updated indication limits the use of pembrolizumab and chemotherapy to tumors expressing PD-L1 as determined by an FDA-approved test.

The combination of SRK-181 and pembrolizumab demonstrated improvements in objective response rate among patients with clear cell renal cell carcinoma in a phase 1 proof-of-concept study.

Selinexor maintenance therapy shows potential in bettering survival compared with placebo in patients with TP53 wild-type recurrent or advanced endometrial cancer.

Findings from the phase 2 RAMP 201 trial show avutometinib plus defactinib demonstrates robust efficacy in patients with recurrent low-grade serious ovarian cancer.

Retrospective data shows that a multidisciplinary surgical approach may improve survival in patients with ovarian cancer.

The combination of dostarlimab and chemotherapy demonstrated meaningful improvements in overall survival for the treatment of primary advanced or recurrent endometrial cancer, according to findings from the phase 3 RUBY trial.

According to findings presented at the Connective Tissue Oncology Society Annual Meeting, INT230-6 enhanced overall survival and disease control rates in relapsed, refractory, and metastatic sarcomas.

In the KEYNOTE-564 trial, patients with renal cell carcinoma who had a nephrectomy achieved improved overall survival rates vs placebo when treated with adjuvant pembrolizumab.

The FDA accepted the new drug application and granted priority review to tovorafenib with a Prescription Drug User Fee Act target date of April 30, 2024.

A phase 2 clinical trial has demonstrated the potential of zanubrutinib combined with R-CHOP for the treatment of untreated diffuse large B-cell lymphoma with extranodal involvement.

SLS009 showed promising efficacy in a phase 1 trial and now has been granted a fast track designation by the FDA for the treatment of relapsed or refractory peripheral T-cell lymphoma.

While response and safety may vary across racial and ethnic subgroups, progression-free survival and overall survival does not appear to differ when chimeric antigen receptor T-cell therapy is used in the treatment of patients with multiple myeloma.

In an interview with Targeted Oncology, Brian Slomovitz, MD, details findings from the innovaTV 301 trial investigating tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer.

The investigational agent is undergoing evaluation in a phase 1/2 trial for the treatment of relapsed or refractory metastatic castration-resistant prostate cancer resistant to androgen receptor pathway inhibitors.

In an interview with Targeted Oncology, Courtney DiNardo, MD, MSCE, discussed what oncologists should know about ivosidenib and the drug’s potential in treating hematologic malignancies.

After issuing a complete response letter in May 2023, the FDA has now accepted the resubmission of the biologics license application of a drug regimen for the treatment of non-muscle-invasive bladder cancer.

A study published in the Journal of the American College of Cardiology found that chimeric antigen receptor T-cell therapy was associated with fewer major cardiac events than previously thought. 

The FDA has expanded the indication of entrectinib for the treatment of pediatric patients 1 month and older with solid tumors harboring an NTRK gene fusion.

Longer follow-up data from the KRYSTAL-7 trial support the initiation of a phase 3 trial evaluating concurrent adagrasib with pembrolizumab in treatment-naïve patients with KRASG12C-mutated non–small cell lung cancer and PD-L1 ≥50%.

Findings from a 5-patient study evaluating azacitidine, venetoclax, and ruxolitinib for the treatment of myeloproliferative neoplasms shows promise. More research is warranted.

The phase 3 CheckMate -67T trial found that a subcutaneous formulation of nivolumab met its co-primary pharmacokinetic end points compared with the intravenous formulation in clear cell renal cell carcinoma.

Neoadjuvant nivolumab and chemotherapy followed by surgery and adjuvant nivolumab demonstrated improvements in event-free survival, pathologic complete response, and major pathologic response in non–small cell lung cancer.

While there was no significant difference in overall survival between the daratumumab and control groups, safety profile results and follow-up data support daratumumab’s continued evaluation in relapsed/refractory multiple myeloma.

Findings from a 3-year follow-up of the Checkmate-816 trial demonstrated promising results with nivolumab and platinum-based chemotherapy, including improvements in event-free survival.

Findings from the CheckMate-901 trial demonstrated improvements for the treatment of patients with urothelial carcinoma who received a combination of nivolumab and chemotherapy followed by nivolumab monotherapy.

A trial of intratumoral daromun and surgical resection for the treatment of patients with locally advanced, fully resectable melanoma, showed a clinically meaningful improvement compared with surgery alone.

Nanrilkefusp alfa did not show sufficient efficacy as a monotherapy or in combination with anti-PD-1 treatments to warrant further development.